MX2020009920A - Tratamiento y profilaxis de amiloidosis. - Google Patents
Tratamiento y profilaxis de amiloidosis.Info
- Publication number
- MX2020009920A MX2020009920A MX2020009920A MX2020009920A MX2020009920A MX 2020009920 A MX2020009920 A MX 2020009920A MX 2020009920 A MX2020009920 A MX 2020009920A MX 2020009920 A MX2020009920 A MX 2020009920A MX 2020009920 A MX2020009920 A MX 2020009920A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- amyloidosis
- prophylaxis
- antibody
- deposition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862647341P | 2018-03-23 | 2018-03-23 | |
| PCT/US2019/023528 WO2019183448A1 (en) | 2018-03-23 | 2019-03-22 | Treatment and prophylaxis of amyloidosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020009920A true MX2020009920A (es) | 2020-12-10 |
Family
ID=66041747
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020009920A MX2020009920A (es) | 2018-03-23 | 2019-03-22 | Tratamiento y profilaxis de amiloidosis. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20210017278A1 (https=) |
| EP (1) | EP3768311A1 (https=) |
| JP (1) | JP7217287B2 (https=) |
| KR (1) | KR20200143400A (https=) |
| CN (1) | CN112040983A (https=) |
| AU (2) | AU2019240413A1 (https=) |
| BR (1) | BR112020019172A2 (https=) |
| CA (1) | CA3095100A1 (https=) |
| EA (1) | EA202092264A1 (https=) |
| MX (1) | MX2020009920A (https=) |
| MY (1) | MY203432A (https=) |
| SG (1) | SG11202009295YA (https=) |
| WO (1) | WO2019183448A1 (https=) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2237803T3 (en) * | 2007-12-28 | 2015-10-05 | Prothena Biosciences Ltd | Treatment and prophylaxis of amyloidosis |
| SG10201604104PA (en) * | 2011-10-25 | 2016-07-28 | Prothena Therapeutics Ltd | Antibody formulations and methods |
| WO2018005967A1 (en) * | 2016-06-30 | 2018-01-04 | Prothena Therapeutics Limited | Compositions for treating amyloidosis |
-
2019
- 2019-03-22 MX MX2020009920A patent/MX2020009920A/es unknown
- 2019-03-22 KR KR1020207030523A patent/KR20200143400A/ko not_active Ceased
- 2019-03-22 WO PCT/US2019/023528 patent/WO2019183448A1/en not_active Ceased
- 2019-03-22 AU AU2019240413A patent/AU2019240413A1/en not_active Abandoned
- 2019-03-22 CA CA3095100A patent/CA3095100A1/en active Pending
- 2019-03-22 MY MYPI2020004912A patent/MY203432A/en unknown
- 2019-03-22 EP EP19715723.3A patent/EP3768311A1/en active Pending
- 2019-03-22 CN CN201980028739.4A patent/CN112040983A/zh active Pending
- 2019-03-22 BR BR112020019172-8A patent/BR112020019172A2/pt not_active Application Discontinuation
- 2019-03-22 US US17/040,343 patent/US20210017278A1/en not_active Abandoned
- 2019-03-22 JP JP2020550650A patent/JP7217287B2/ja active Active
- 2019-03-22 EA EA202092264A patent/EA202092264A1/ru unknown
- 2019-03-22 SG SG11202009295YA patent/SG11202009295YA/en unknown
-
2023
- 2023-04-05 AU AU2023202109A patent/AU2023202109A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3768311A1 (en) | 2021-01-27 |
| MY203432A (en) | 2024-06-27 |
| CN112040983A (zh) | 2020-12-04 |
| CA3095100A1 (en) | 2019-09-26 |
| BR112020019172A2 (pt) | 2021-01-26 |
| KR20200143400A (ko) | 2020-12-23 |
| AU2023202109A1 (en) | 2023-05-18 |
| EA202092264A1 (ru) | 2020-12-03 |
| JP7217287B2 (ja) | 2023-02-02 |
| WO2019183448A1 (en) | 2019-09-26 |
| AU2019240413A1 (en) | 2020-10-08 |
| US20210017278A1 (en) | 2021-01-21 |
| JP2021518393A (ja) | 2021-08-02 |
| SG11202009295YA (en) | 2020-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR132864A2 (es) | UN ANTICUERPO QUE SE UNE ESPECÍFICAMENTE A a-SINUCLEÍNA HUMANA, UN ANTICUERPO HUMANIZADO, UNA FORMULACIÓN FARMACÉUTICA QUE COMPRENDE EL ANTICUERPO, Y LA UTILIZACIÓN DEL ANTICUERPO | |
| CY1124521T1 (el) | Σκευασματα αντισωματος anti-cd19 | |
| CO2019009680A2 (es) | Anticuerpo anti-gprc5d y molécula que comprende el anticuerpo | |
| ECSP21033236A (es) | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp | |
| MX2017006626A (es) | Cadenas ligeras comunes y metodos de uso. | |
| CL2018001705A1 (es) | Composición farmacéutica que comprende lenalidomida amorfa y un antioxidante. | |
| CL2018000819A1 (es) | Anticuerpos biespecíficos anti-cd20 humano/receptor de transferrina humano y métodos para su uso | |
| CL2017003023A1 (es) | Anticuerpos anti-ctla-4 y métodos de uso de los mismos. | |
| CL2021001395A1 (es) | Compuestos derivados de panteteínas cíclicas; composición farmacéutica que los comprende; y su uso para aumentar las concentraciones de acetil-coa, para el tratamiento de cáncer, enfermedad inflamatoria, enfermedad neurodegenerativa, esclerosis múltiple, entre otras enfermedades. | |
| MX2019012978A (es) | Composiciones para el cuidado bucal y metodos para utilizar las composiciones. | |
| MX2017012802A (es) | Anticuerpos antisortilina y métodos para su uso. | |
| AR114565A1 (es) | Proteínas de fusión fc il-22 y métodos de uso | |
| MX2016009625A (es) | Proteinas quimericas tipo fosfatasa alcalina. | |
| MX2016016301A (es) | Procesos de siembra en serie y usos de los mismos. | |
| MX2020003581A (es) | Compuestos monobactamicos cromanos para el tratamiento de infecciones bacterianas. | |
| ECSP19057403A (es) | Usos terapéuticos de un polvo de insectos | |
| MX2019009908A (es) | Combinacion de un agonista de ppar con un agonista de fxr. | |
| MX2021004774A (es) | Formulacion de anticuerpos. | |
| EP3884663A4 (en) | MULTI-WAVELENGTH VISIBLE LASER SOURCE | |
| MX2019012865A (es) | Anticuerpos anti-interferon gamma y usos de los mismos. | |
| CL2021002318A1 (es) | Métodos de tratamiento de amiloidosis al | |
| MX2020011027A (es) | Constructos de anticuerpos biespecíficos trivalentes. | |
| CO2020000260A2 (es) | Anticuerpos quiméricos para el tratamiento de enfermedades de deposición del amiloide | |
| CO2021010786A2 (es) | Toxinas apxia, apxiia y apxiiia inactivadas | |
| CO2017002614A2 (es) | Vacuna emulsionada para obtener formulaciones de inmunoglobulinas igy concentradas; procesos y usos de las mismas. |